Ohio Study Shows Access To Naloxone Soars Without Rx Requirement
Executive Summary
JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.
You may also be interested in...
Australian Pharmacists Support Providing Nonprescription Naloxone But Training Unavailable
Two studies revealed a lack of knowledge by pharmacists in Australia about providing naloxone despite being available without a prescription from pharmacists since 2016. Results could be an indication of potential problems if the opioid antagonist is made available nonprescription in US.
Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private
Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.
OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy
Up to $6.5m funding will completely cover Harm Reduction Therapeutics' costs for a Phase 1 study, preparation of an NDA and commercial launch production. The study, a standard Phase 1 biocompatibility trial with around 30 subjects, should be completed in a few months later this summer.